Pulmonary emphysema and coronary artery calcifications at baseline LDCT and long-term mortality in smokers and former smokers of the ITALUNG screening trial.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
May 2023
Historique:
received: 11 11 2022
accepted: 03 02 2023
revised: 01 02 2023
medline: 25 4 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

Cardiovascular disease (CVD), lung cancer (LC), and respiratory diseases are main causes of death in smokers and former smokers undergoing low-dose computed tomography (LDCT) for LC screening. We assessed whether quantification of pulmonary emphysematous changes at baseline LDCT has a predictive value concerning long-term mortality. In this longitudinal study, we assessed pulmonary emphysematous changes with densitometry (volume corrected relative area below - 950 Hounsfield units) and coronary artery calcifications (CAC) with a 0-3 visual scale in baseline LDCT of 524 participants in the ITALUNG trial and analyzed their association with mortality after 13.6 years of follow-up using conventional statistics and a machine learning approach. Pulmonary emphysematous changes were present in 32.3% of subjects and were mild (6% ≤ RA950 ≤ 9%) in 14.9% and moderate-severe (RA950 > 9%) in 17.4%. CAC were present in 67% of subjects (mild in 34.7%, moderate-severe in 32.2%). In the follow-up, 81 (15.4%) subjects died (20 of LC, 28 of other cancers, 15 of CVD, 4 of respiratory disease, and 14 of other conditions). After adjusting for age, sex, smoking history, and CAC, moderate-severe emphysema was significantly associated with overall (OR 2.22; 95CI 1.34-3.70) and CVD (OR 3.66; 95CI 1.21-11.04) mortality. Machine learning showed that RA950 was the best single feature predictive of overall and CVD mortality. Moderate-severe pulmonary emphysematous changes are an independent predictor of long-term overall and CVD mortality in subjects participating in LC screening and should be incorporated in the post-test calculation of the individual mortality risk profile. • Densitometry allows quantification of pulmonary emphysematous changes in low-dose CT examinations for lung cancer screening. • Emphysematous lung density changes are an independent predictor of long-term overall and cardio-vascular disease mortality in smokers and former smokers undergoing screening. • Emphysematous changes quantification should be included in the post-test calculation of the individual mortality risk profile.

Identifiants

pubmed: 36854875
doi: 10.1007/s00330-023-09504-4
pii: 10.1007/s00330-023-09504-4
pmc: PMC10121526
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3115-3123

Informations de copyright

© 2023. The Author(s).

Références

Eur Respir J. 2012 Nov;40(5):1142-8
pubmed: 22408202
J Thorac Oncol. 2013 Jul;8(7):866-75
pubmed: 23612465
Int J Cancer. 2021 Jul 15;149(2):250-263
pubmed: 33783822
JAMA. 2021 Mar 09;325(10):962-970
pubmed: 33687470
Eur Respir J. 2021 Sep 2;58(3):
pubmed: 33574075
Radiology. 2012 Feb;262(2):460-7
pubmed: 22114241
J Am Geriatr Soc. 2001 May;49(5):571-6
pubmed: 11380749
Eur Radiol. 2009 Jul;19(7):1686-92
pubmed: 19224221
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
J Thorac Dis. 2017 Sep;9(9):3319-3345
pubmed: 29221318
AJR Am J Roentgenol. 2020 Jun;214(6):1269-1279
pubmed: 32255690
Thorax. 2014 Aug;69(8):718-23
pubmed: 24473329
Transl Lung Cancer Res. 2022 Sep;11(9):1896-1911
pubmed: 36248328
Eur Radiol. 2009 Jan;19(1):58-66
pubmed: 18690451
Radiology. 2015 Jul;276(1):82-90
pubmed: 25759972
Med Phys. 2020 Jul;47(7):2962-2969
pubmed: 32160310
Eur Radiol. 2014 Nov;24(11):2692-9
pubmed: 25038853
AJR Am J Roentgenol. 2014 Oct;203(4):W383-90
pubmed: 25247967
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750524
pubmed: 29355081
Br J Radiol. 2012 Aug;85(1016):1134-9
pubmed: 21976631
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Chest. 2008 Dec;134(6):1244-1249
pubmed: 18641115
Acad Radiol. 2010 Feb;17(2):146-56
pubmed: 19931472
Chest. 2021 May;159(5):1812-1820
pubmed: 33326807
BMC Bioinformatics. 2006 Feb 23;7:91
pubmed: 16504092
Lung Cancer. 2009 Apr;64(1):34-40
pubmed: 18723240
Int J Chron Obstruct Pulmon Dis. 2016 Sep 14;11:2229-2236
pubmed: 27695310
Eur J Radiol. 2021 Dec;145:110040
pubmed: 34814037
Thorax. 2010 Aug;65(8):719-25
pubmed: 20685748
Eur Heart J Cardiovasc Imaging. 2013 Dec;14(12):1159-66
pubmed: 23639550
Eur Radiol. 2015 Jan;25(1):65-71
pubmed: 25182625
Radiology. 2015 Oct;277(1):192-205
pubmed: 25961632
Thorax. 2020 Aug;75(8):617-618
pubmed: 32631934
Chest. 2022 Apr;161(4):1092-1100
pubmed: 34838524
Thorax. 2017 Sep;72(9):825-831
pubmed: 28377492
Thorax. 2019 Sep;74(9):825-827
pubmed: 31363021
JAMA Intern Med. 2015 Sep;175(9):1539-49
pubmed: 26098755
Scand Cardiovasc J. 2015 Jun;49(3):159-67
pubmed: 25919145
Ann Oncol. 2019 Jul 1;30(7):1162-1169
pubmed: 30937431
Proc Am Thorac Soc. 2005;2(1):8-11
pubmed: 16113462

Auteurs

Mario Mascalchi (M)

Department of Clinical and Experimental, Biomedical Sciences "Mario Serio, " University of Florence, Viale Pieraccini, 50134, Florence, Italy. mario.mascalchi@unifi.it.
Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy. mario.mascalchi@unifi.it.
Division of Cancer Epidemiology (C020), German Cancer Research Center (DKFZ), Heidelberg, Germany. mario.mascalchi@unifi.it.

Chiara Romei (C)

Division of Radiology, Cisanello Hospital, Pisa, Italy.

Chiara Marzi (C)

"Nello Carrara" Institute of Applied Physics, National Research Council of Italy, Sesto Fiorentino, Florence, Italy.

Stefano Diciotti (S)

Department of Electrical, Electronic, and Information Engineering 'Guglielmo Marconi', University of Bologna, Bologna, Italy.

Giulia Picozzi (G)

Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy.

Francesco Pistelli (F)

Pulmonary Unit, Cardiothoracic and Vascular Department, Pisa University Hospital, Pisa, Italy.

Marco Zappa (M)

Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy.

Eugenio Paci (E)

Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy.

Francesca Carozzi (F)

Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Giuseppe Gorini (G)

Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy.

Fabio Falaschi (F)

Division of Radiology, Cisanello Hospital, Pisa, Italy.

Anna Lisa Deliperi (AL)

Division of Radiology, Cisanello Hospital, Pisa, Italy.

Gianna Camiciottoli (G)

Department of Clinical and Experimental, Biomedical Sciences "Mario Serio, " University of Florence, Viale Pieraccini, 50134, Florence, Italy.

Laura Carrozzi (L)

Pulmonary Unit, Cardiothoracic and Vascular Department, Pisa University Hospital, Pisa, Italy.

Donella Puliti (D)

Division of Epidemiology and Clinical Governance, Institute for Study, PRevention and netwoRk in Oncology (ISPRO), Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH